PCSA · Processa Pharmaceuticals Inc
United States · RS rating 39 · As of 2026-11-03
| Price | 1.94 USD |
|---|---|
| 1-day change | +4.9% |
| RS rating (overall / 1M / 3M / 12M) | 39 / 96 / 43 / 9 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 22 / 15 / 26 |
| Industry group (rank) | Medical-Ethical Drugs (94) |
| EPS growth Q/Q | +7.8% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +79.0% |
| Market cap (USD) | $8.0M |